292 related articles for article (PubMed ID: 20375898)
1. Pleural effusions due to dasatinib.
Brixey AG; Light RW
Curr Opin Pulm Med; 2010 Jul; 16(4):351-6. PubMed ID: 20375898
[TBL] [Abstract][Full Text] [Related]
2. New approved dasatinib regimen available for clinical use.
Snyder DS
Expert Rev Anticancer Ther; 2009 Mar; 9(3):285-92. PubMed ID: 19275507
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
4. Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.
Breccia M; Alimena G
Expert Opin Drug Saf; 2010 Sep; 9(5):713-21. PubMed ID: 20722490
[TBL] [Abstract][Full Text] [Related]
5. Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.
Tyler T
Ann Pharmacother; 2009 May; 43(5):920-7. PubMed ID: 19336654
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib-induced pleural effusions: a lymphatic network disorder?
Goldblatt M; Huggins JT; Doelken P; Gurung P; Sahn SA
Am J Med Sci; 2009 Nov; 338(5):414-7. PubMed ID: 19838099
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events.
Shayani S
Ther Drug Monit; 2010 Dec; 32(6):680-7. PubMed ID: 20864900
[TBL] [Abstract][Full Text] [Related]
8. [Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib].
Hoshino T; Tahara K; Miyawaki K; Hatsumi N; Takada S; Miyawaki S; Sakura T
Rinsho Ketsueki; 2010 Mar; 51(3):181-8. PubMed ID: 20379112
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
Lilly MB; Ottmann OG; Shah NP; Larson RA; Reiffers JJ; Ehninger G; Müller MC; Charbonnier A; Bullorsky E; Dombret H; Brigid Bradley-Garelik M; Zhu C; Martinelli G
Am J Hematol; 2010 Mar; 85(3):164-70. PubMed ID: 20131302
[TBL] [Abstract][Full Text] [Related]
11. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.
Latagliata R; Breccia M; Fava C; Stagno F; Tiribelli M; Luciano L; Gozzini A; Gugliotta G; Annunziata M; Cavazzini F; Ferrero D; Musto P; Capodanno I; Iurlo A; Visani G; Crugnola M; Calistri E; Castagnetti F; Vigneri P; Alimena G
Hematol Oncol; 2013 Jun; 31(2):103-9. PubMed ID: 22815278
[TBL] [Abstract][Full Text] [Related]
12. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series.
Bergeron A; Réa D; Levy V; Picard C; Meignin V; Tamburini J; Bruzzoni-Giovanelli H; Calvo F; Tazi A; Rousselot P
Am J Respir Crit Care Med; 2007 Oct; 176(8):814-8. PubMed ID: 17600277
[TBL] [Abstract][Full Text] [Related]
13. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
Quintás-Cardama A; Kantarjian H; O'brien S; Borthakur G; Bruzzi J; Munden R; Cortes J
J Clin Oncol; 2007 Sep; 25(25):3908-14. PubMed ID: 17761974
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Keam SJ
BioDrugs; 2008; 22(1):59-69. PubMed ID: 18215092
[TBL] [Abstract][Full Text] [Related]
15. The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.
Masiello D; Gorospe G; Yang AS
J Hematol Oncol; 2009 Nov; 2():46. PubMed ID: 19909541
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia.
Wong SF
J Oncol Pharm Pract; 2009 Mar; 15(1):17-27. PubMed ID: 18753186
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib.
Lindauer M; Hochhaus A
Recent Results Cancer Res; 2010; 184():83-102. PubMed ID: 20072833
[TBL] [Abstract][Full Text] [Related]
18. [Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias].
Cony-Makhoul P; Bergeron A; Corm S; Dubruille V; Rea D; Rigal-Huguet F; Nicolini FE
Bull Cancer; 2008 Sep; 95(9):805-11. PubMed ID: 18829412
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect?
Paydas S
Crit Rev Oncol Hematol; 2014 Feb; 89(2):242-7. PubMed ID: 24210599
[TBL] [Abstract][Full Text] [Related]
20. Management of Bcr-Abl-positive leukemias with dasatinib.
Hochhaus A
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1529-36. PubMed ID: 18020922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
